Summit Therapeutics Inc. Common Stock (SMMT) carries a Roarable Rating of C (Hold) with 63/100 RQD Confidence. The underlying business is intact, so current owners don’t need to panic-sell—but mixed big-money flow or rich pricing means new buyers can afford to wait for either a pullback or a B-or-higher upgrade.
Summit Therapeutics Inc. Common Stock (SMMT) surged +2.73% to $16.20 as options desks priced 61% call premium vs. 39% put protection around the $16 max-pain magnet. Solid 41% profit margin (-35% return on capital), mixed timing at current multiples—hold if owned, no rush to chase.
Summit Therapeutics (SMMT) has packed October with pipeline moves, including a new Phase II kidney cancer study, a Phase II/III biliary tract cancer trial and an AI pathology research deal. Those October trial launches a
AstraZeneca beats Q3 earnings and revenue estimates as oncology sales surge 17%, offsetting generic pressure on mature drugs.
MercadoLibre, Novo Nordisk, Tyler Technologies and Summit Therapeutics trade below recent highs, yet each has earnings or catalysts that could shift sentiment.
Lunit will examine haematoxylin and eosin-stained whole-slide images to profile tumour microenvironment characteristics.
MIAMI, October 25, 2026--Summit Therapeutics Inc. (Nasdaq: SMMT) today noted that its partner Akeso Inc. announced positive results from the Phase III HARMONi-GI1 study evaluating the novel, potential first-in-class inve
Lunit Inc. (KRX: 328130) and Summit Therapeutics Inc. (NASDAQ: SMMT) today announced a research agreement to evaluate the use of Lunit SCOPE IO, Lunit's AI-powered pathology platform, for tumor microenvironment analysis
MIAMI & SEOUL, South Korea, October 23, 2026--Summit Therapeutics Inc. (NASDAQ: SMMT) and Lunit Inc. (KRX: 328130) today announced a research agreement to evaluate the use of Lunit SCOPE IO, Lunit’s AI-powered pathology
The prohibitions could cut off Big Pharma from Chinese biotechs—the source of many promising cancer treatments
SMMT is advancing ivonescimab into BTC, launching a phase II/III study to compare its survival benefits with established immunotherapy regimens.
MIAMI, October 22, 2026--Summit Therapeutics Inc. (NASDAQ: SMMT) today announced that ivonescimab data will be featured in numerous presentations at the European Society for Medical Oncology 2026 Congress (ESMO 2026), ta
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +11.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on SMMT today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for SMMT. Explore sector supply chains on /butterfly.
Why SMMT Stock surged +2.73% Today — RQD Quant Desk Flash. Solid 41% profit margin (-35% return on capital), mixed timing at current multiples—hold if owned, no rush to chase.